{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-262950","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2026-06-09T11:03:35+00:00","discovered_at":"2026-06-09T11:05:00.236411+00:00","generated_at":"2026-06-09T11:05:13.797449+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"GSK to acquire Nuvalent for $124/share (~$10.6B); assets under FDA review for 2026 approval","bullets":["All-share tender offer at $124.00 per share; aggregate equity value ~$10.6B; net cash investment ~$9.4B.","40% premium to last closing price; 26% premium to 30-day VWAP; no financing condition.","Deal includes late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib; FDA decisions due Sept/Nov 2026.","Supporting stockholders (~28% of Class A shares) have agreed to tender; termination fee $350.5M.","Transaction expected to close Q3 2026; GSK expects accretion to operating profit in 2027, EPS in 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-262950","json":"https://secwatch.observer/filing/0001193125-26-262950.json","markdown":"https://secwatch.observer/filing/0001193125-26-262950.md","text":"https://secwatch.observer/filing/0001193125-26-262950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/0001193125-26-262950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/d137459d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:05:13.797449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b81dbd3381fb77b58fb9f70dcaca25fa1b251deb","claim":"Nuvalent, Inc. entered into Agreement and Plan of Merger with GlaxoSmithKline LLC, Harmony Row Acquisition Co., and GSK plc valued at $124.00 per Share (effective 2026-06-09).","evidence_excerpt":"On June 9, 2026, Nuvalent, Inc., a Delaware corporation (the “ Company ” or “ Nuvalent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with GlaxoSmithKline LLC, a Delaware limited liability company (“ Parent ”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“ Ultimate Parent ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/0001193125-26-262950-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"GlaxoSmithKline LLC, Harmony Row Acquisition Co., and GSK plc"},{"label":"Value","value":"$124.00 per Share"},{"label":"Effective","value":"2026-06-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}